A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia (NCT05648968)

🧪 Interventions in This Study

• Ianalumab (BIOLOGICAL)
• Placebo (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (53 Sites)

Showing the first 25 of 53 sites.

• Michigan Center of Medical Research — Farmington Hills, Michigan
• University of Minnesota Med Center — Minneapolis, Minnesota
• Fred Hutchinson Cancer Center — Seattle, Washington
• Novartis Investigative Site — CABA, Buenos Aires
• Novartis Investigative Site — Buenos Aires,
• Novartis Investigative Site — Caba,
• Novartis Investigative Site — Garran, Australian Capital Territory
• Novartis Investigative Site — Melbourne, Victoria
• Novartis Investigative Site — Guangzhou, Guangdong
• Novartis Investigative Site — Hangzhou, Zhejiang
• Novartis Investigative Site — Dalian,
• Novartis Investigative Site — Tianjin,
• Novartis Investigative Site — Tianjin,
• Novartis Investigative Site — Créteil,
• Novartis Investigative Site — Lille,
• Novartis Investigative Site — Nantes,
• Novartis Investigative Site — Nice,
• Novartis Investigative Site — Dresden,
• Novartis Investigative Site — Essen,
• Novartis Investigative Site — Giessen,
• Novartis Investigative Site — Hanover,
• Novartis Investigative Site — Debrecen, Hajdu Bihar Megye
• Novartis Investigative Site — New Delhi, National Capital Territory of Delhi
• Novartis Investigative Site — Madurai, Tamil Nadu
• Novartis Investigative Site — Hyderabad, Telangana

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Warm Autoimmune Hemolytic Anemia (wAIHA)

• Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA) — Cerritos, California
• Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease — Rochester, Minnesota

Explore by condition: All Warm Autoimmune Hemolytic Anemia (wAIHA) clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.